What is your preferred third line approach for a patient with refractory small cell lung cancer who has failed second line therapy with nivolumab after recieving first line platinum based therapy ?

Would you offer immunotherapy combination (nivo/ipi) in patients who have failed nivolumab mono-therapy?

Answer from: Medical Oncologist at Academic Institution

I would prefer a clinical trial or perhaps a taxane, but I have added ipilimumab to nivolumab in this situation, despite the lack of data. The results remain to be seen!

Please select the option that best describes you:

What is your preferred third line approach for a patient with refractory small cell lung cancer who has failed second line therapy with nivolumab after recieving first line platinum based therapy ?

Related Questions